Veloxis Pharmaceuticals, Inc.

Veloxis Pharmaceuticals, Inc. is a specialty pharmaceutical company headquartered in Cary, North Carolina. Founded in 2002 as a spin-off from H. Lundbeck A/S, the company was acquired by the Japanese firm Asahi Kasei in March 2020 for approximately $1.3 billion. Veloxis now operates as a wholly-owned indirect subsidiary and part of Asahi Kasei's global healthcare business. Publicly available information from 2024 indicates the company has approximately 116 employees.

Veloxis is an operating company focused on the development and commercialization of immunosuppressive drugs for organ transplant recipients. Its primary product is ENVARSUS XR® (tacrolimus extended-release tablets), a once-daily medication used to prevent organ rejection in kidney transplant patients. The company utilizes its proprietary MeltDose® drug delivery technology, which is designed to improve the absorption and bioavailability of certain oral medications. Veloxis is also developing a pipeline product, VEL-101 (pegrizeprument), an investigational agent for the prevention of acute rejection in solid organ transplant recipients.

The company's patent litigation history shows it acts as an enforcement entity for its own products. All six of its tracked patent cases have been filed as a plaintiff, with zero cases as a defendant. This posture is typical of a pharmaceutical brand owner suing generic drug manufacturers for patent infringement under the Hatch-Waxman Act. All of its lawsuits have been filed in the U.S. District Court for the District of Delaware, a common venue for pharmaceutical patent litigation.

The defendants in Veloxis's lawsuits are generic pharmaceutical manufacturers, including Glenmark Pharmaceuticals Inc., Alkem Laboratories Ltd., Sun Pharmaceutical Industries Ltd., and Accord Healthcare, Inc. These cases are consistent with a strategy of defending the patent portfolio of its key commercial product, ENVARSUS XR, against companies seeking to market generic versions. The lawsuits allege infringement of patents covering the drug product and its formulation.